ViiV Preps Once-Daily Integrase Inhibitor '572 For Phase III

Phase II results presented at International AIDS Society meeting fuel speculation about co-formulations with other HIV drugs, including ViiV's Epzicom and Gilead's Truvada.

More from Archive

More from Pink Sheet